Hyperprolactinemia; etiology, diagnosis and treatment alternatives

Acta Obstetricia et Gynecologica Scandinavica

Volumn 77, Issue 3, 1998, Pages 249-262

  Conner, Peter ^a   Fried, Gabriel ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Hyperprolactinemia; Lactation; Pituitary gland; Pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; BROMOCRIPTINE LAR; CABERGOLINE; CLOZAPINE; ESTROGEN; LITHIUM; NEUROLEPTIC AGENT; PERGOLIDE; PROLACTIN; QUINAGOLIDE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; CEREBROVASCULAR DISEASE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; ESTROGEN THERAPY; GALACTORRHEA; HEADACHE; HEART INFARCTION; HORMONE STRUCTURE; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; HYPOTHYROIDISM; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; OVARY POLYCYSTIC DISEASE; PATHOLOGY; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; PSYCHOSIS; REVIEW; UTERUS CANCER; VERTIGO; VOMITING;

EID: 0031885840     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1080/j.1600-0412.1998.770301.x     Document Type: Review

References (57)

1. Rasmussen C. Hyperprolactinaemia - a clinical study with special reference to long term follow-up, treatment with dopamine agonists, and pregnancy. Doctoral thesis at the Uppsala University, 1989 from the Department of Obstetrics and Gynaecology.
2. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. 5th ed. Baltimore: Williams & Wilkins, 1994.
3. Brue T, Caruso E, Morange I et al. Immunoradiometric analysis of circulating human glycosylated and nonglycosylated prolactin forms; spontaneous and stimulated secretions. J Clin Endocrinol Metab 1992; 75: 1338-44.
4. Lindstedt G. Endogenous antibodies against prolactin - a new cause of hyperprolactinemia. Eur J Endocrinol 1994; 130: 429-3.
5. Hattori N, Ishihara T, Ikekubo K, Moridera K, Hino M, Kurahachi H. A normal ovulatory woman with hyperprolactinemia; presence of anti-prolactin autoantibody and the regulation of prolactin secretion. Acta Endocrinol 1992; 126: 497-500.
6. Lindstedt G, Edèn S. Antikroppar mot prolactin. (Antibodies against prolactin.) (in Swedish.) Läkartidningen 1994; 91: 32-3.
7. Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 1992; 21: 877-901.
8. Blackwell RE. Hyperprolactinemia; Evaluation and management. Reprod Endocrinol 1992; 21: 105-24.
9. Sarapura V, Schlaff W. Recent advances in the understanding of the pathophysiology and treatment of hyperprolactinemia. Curr Opin Obstet Gynecol 1993; 5: 360-7.
10. Falk RJ. Isolated prolactin deficiency a case report. Fertil Steril 1992; 58: 1060-2.
11. 2 receptor and pituitary tumors. Clin Endocrinol 1991; 35: 455-66.
12. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 220-40.
13. Besser GM, Lamberts SWJ. CV 205-502. 1st International Round Table Conference. The Netherlands: Medicom Europe, 1990.
14. Asukai K, Uemura T Minaguchi H. Occult hyperprolactinemia in infertile women. Fertil Steril 1993; 60: 423-7.
15. Huang K, Bonfiglio TA, Muechler EK. Transient hyperprolactinemia in infertile women with luteal phase deficiency. Obstet Gynecol 1991; 78: 651-5.
16. Crosignani PG, Maini MC, Negri E, Ragni G. Human prolactin release induced by follicle stimulating hormone, luteinizing hormone and human chorionic gonadotropin. Hum Reprod 1991; 6: 1070-3.
17. Inaudi P, Genazzani AD, Reymond MJ, Lemarchand-Beraud T, Rey F. Pulsatile secretion of gonadotropins and prolactin during the follicular and luteal phases of the menstrual cycle; analysis of instantaneous secretion rate and secretory concomitance. Fertil Steril 1992; 58: 51-9.
18. Lebrun JJ, Ali S, Ullrich A, Kelly PA. Proline-rich sequence-mediated Jak2 association to the prolactin receptor is required but not sufficient for signal transduction. J Biol Chem 1995; 270: 10664-70.
19. Chang WP, Clevenger CV Modulation of growth factor receptor function by isoform heterodimerization. Proc Natl Acad Sci USA 1996; 93: 5947-52.
20. Prevarskaya NB, Skryma RN, Vacher P, Daniel N, Djiane J, Dufy B. Role of tyrosine phosphorylation in potassium channel activation. Functional association with prolactin receptor and JAK2 tyrosine kinase. J Biol Chem 1995; 270: 24292-9.
21. Groner B, Gouilleux F. Prolactin-mediated gene activation in mammary epithelial cells. [Review] Curr Opin Genet Dev 1995; 5: 587-94.
22. Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 1995; 92: 8831-5.
23. Berlanga JJ, Fresno Vara JA, Martin-Perez J, Garcia-Ruiz JP. Prolactin receptor is associated with c-src kinase in rat liver. Mol Endocrinol 1995; 9: 1461-7.
24. Batrinos ML, Panitsa-Faflia C, Tsiganou E, Pitoulis G, Liapi C. Contribution to the problem of hyperprolactinemia, experience with 4199 prolactin assays and 117 prolactinomas. Int J Fertil Menopausal Stud 1994; 39: 120-7.
25. Batrinos ML, Panitsa-Faflia CH, Tsiganou E, Liapi CH. Incidence and characteristics of microprolactinomas (3-5 mm) in 4199 women assayed for prolactin. Horm Metab Res 1992; 24: 384-91.
26. Stewart PM, Maheshwaran S, Griffith J et al. Pituitary imaging is essential for women with moderate hyperprolactinemia. BMJ 1993; 306: 507-8.
27. Gadir AA, Khatim MS, Muharib NS, Shaw RW The aetiology of galactorrhea in women with regular menstruation and normal prolactin levels. Hum Reprod 1992; 7: 912-14.
28. Padilla SL, Persson GK, McDonough PG, Reindollar RH. The efficacy of bromocriptine in patients with ovulatory dysfunction and normoprolactinemic galactorrhea. Fertil Steril 1985; 44: 695-8.
29. Serri O. Progress in the management hyperprolactinemia. N Engl J Med 1994; 331: 942-4.
30. Marken PA, Haykal RF, Fischer JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992; 11: 851-6.
31. Falashi P, Rocco A, Del Pozo E. Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome. J Clin Endocrinol Metab 1986; 62: 348-51.
32. Sluijmer AV, Lappöhn RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 1992; 58: 72-7.
33. Cunnah D, Besser M. Management of prolactinomas. Clin Endocrinol 1991; 34: 231-5.
34. Donovan LE, Corenblum B. The natural history of the pituitary incidentaloma. Arch Intern Med 1995; 155: 181-3.
35. Peillon F, Dupuy M, Li JY et al. Pituitary enlargement with suprasellar extension in functional hyperprolactinemia due to lactotroph hyperplasia; a pseudotumoral disease. J Clin Endocrinol Metab 1991; 73: 1008-15.
36. Ampudia X, Puig-Domingo M, Schwarzstein D et al. Outcome and long term effects of pregnancy in women with hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol 1992; 46: 101-7.
37. Ciccarelli E, Miola C, Avataneo T, Camanni F, Besser GM, Grossman A. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR. in patients with tumorous hyperprolactinemia. Fertil Steril 1989; 52: 930-5.
38. Lamberts SWJ, Quik RFP. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1991; 72: 635.
39. Van't Verlaat JW, Croughs JM. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol 1991; 34: 175-8.
40. Ginsburg J, Hardiman P, Thomas M. Vaginal bromocriptine-clinical and biochemical effects. Gynecol Endocrinol 1992; 6: 119-26.
41. Kulig K, Moore LL, Kirk M, Smith D, Stallworth J, Rumack B. Bromocriptine-associated headache; possible life threatening sympatomimetic interaction. Obstet Gynecol 1991; 78: 941-3.
42. Jasonni VM, Raffelli R, De March A, Frank G, Flamigni C. Vaginal bromocriptine in hyperprolactinemic patients and puerperal women. Acta Obstet Gynecol Scand 1991; 70: 493-5.
43. Chan CLK, Devendra S, Yang M, Ng SC, Ratnam SS. Report on pregnancies in three patients with resistant hyperprolactinemia treated with long-acting repeatable bromocriptine injections. Am J Clin Research 1994; 3: 9-14.
44. Lengyel AMJ, Mussio W, Imamura P, Viera JGH, Lancranjan I. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas. Fertil Steril 1993; 59: 980-7.
45. Espinos JJ, Rodriguez-Espinosa J, Webb SM, Calaf-Alsina J. Long-term repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics. Fertil Steril 1994; 62: 926-31.
46. Weingrill CO, Mussio W, Monies CRS, Portes E, Castro RC, Lengyel AMJ. Long acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia. Fertil Steril 1992, 57: 331-5.
47. Cicinelli E, Petruzzi D, Ragno G, Schönauer LM, Ruccia C, Mateo G. Nasal spray bromocriptine: Effects on serum prolactin in puerperal women. Acta Obstet Gynecol Scand 1996; 75: 730-3.
48. Van Der Lely AJ, Brownell J, Lamberts SWJ. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991; 72: 1136-41.
49. Webster J, Piscitelli G, Polli A et al. The efficacy and tolerability of long term cabergoline therapy in hyperprolactinaemic disorders: An open, uncontrolled, multicentre study. European multicentre cabergoline study group. Clin Endocrinol 1993; 39: 323-9.
50. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 1994; 331: 904-9.
51. Rolland R, Piscilelli G, Ferrari C, Petroccione A. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. BMJ 1991; 302: 1367-71.
52. Brue T, Pellegrini I. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992; 74: 577-84.
53. Webster J, Page MD, Bevan JS, Richards SH, Douglas-Jones AG, Scanlon MF. Low recurrence rate after partial hypophysectomy tor prolactinoma; the predictive value of dynamic prolactin function tests. Clin Endocrinol 1992; 36: 35-44.
54. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993; 59: 671-3.
55. Fahy UM, Foster PA, Torode HW, Hartog M, Hull GR. The effect of combined estrogen/ progesterone treatment in women with hyperprolactinemic amenorrhea. Gynecol Endocrinol 1992; 6: 183-8.
56. Torring O, Isberg B, Sjöberg HE, Bucht E, Hulting AL. Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment. Acta Endocrinol 1993; 128: 423-7.
57. Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992; 75: 698-703.